PROSTIN VR PEDIATRIC - Pharmacia & Upjohn Company LLC

Manufacturer
Pharmacia & Upjohn Company LLC
Effective date
2026-08-17
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
daily-update
Hydrated at
2026-08-26 01:04:38

Label at a glance#

ProductPROSTIN VR PEDIATRIC
Active ingredientALPROSTADIL
Label structure15 sections

Boxed warning

Apnea is experienced by about 10 to 12% of neonates with congenital heart defects treated with PROSTIN VR PEDIATRIC Sterile Solution. Apnea is most often seen in neonates weighing less than 2 kg at birth and usually appears during the first hour of drug infusion. Therefore, respiratory status should be monitored throughout treatment, and PROSTIN VR PEDIATRIC should be used where ventilatory assistance is immediate...

Indications and uses

PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fa...

Dosage and administration

The preferred route of administration for PROSTIN VR PEDIATRIC Sterile Solution is continuous intravenous infusion into a large vein. Alternatively, PROSTIN VR PEDIATRIC may be administered through an umbilical artery catheter placed at the ductal opening. Increases in blood pO 2 (torr) have been the same in neonates who received the drug by either route of administration. Begin infusion with 0.05 to 0.1 microgram...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

500 micrograms per mL

WARNING

Boxed Warning section

Apnea is experienced by about 10 to 12% of neonates with congenital heart defects treated with PROSTIN VR PEDIATRIC Sterile Solution. Apnea is most often seen in neonates weighing less than 2 kg at birth and usually appears during the first hour of drug infusion. Therefore, respiratory status should be monitored throughout treatment, and PROSTIN VR PEDIATRIC should be used where ventilatory assistance is immediately available.

DESCRIPTION

DESCRIPTION SECTION

PROSTIN VR PEDIATRIC Sterile Solution for intravascular infusion contains 500 micrograms alprostadil, more commonly known as prostaglandin E1, in 1.0 mL dehydrated alcohol.

The chemical name for alprostadil is (11α,13E,15S)-11,15 dihydroxy-9-oxo-prost-13-en-1-oic acid, and the molecular weight is 354.49.

Alprostadil is a white to off-white crystalline powder with a melting point between 110° and 116°C. Its solubility at 35°C is 8000 micrograms per 100 mL double distilled water.

Structural Formula

Chemical Structure
Chemical Structure

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Alprostadil (prostaglandin E1) is one of a family of naturally occurring acidic lipids with various pharmacologic effects. Vasodilation, inhibition of platelet aggregation, and stimulation of intestinal and uterine smooth muscle are among the most notable of these effects. Intravenous doses of 1 to 10 micrograms of alprostadil per kilogram of body weight lower the blood pressure in mammals by decreasing peripheral resistance. Reflex increases in cardiac output and rate accompany the reduction in blood pressure.

Smooth muscle of the ductus arteriosus is especially sensitive to alprostadil, and strips of lamb ductus markedly relax in the presence of the drug. In addition, administration of alprostadil reopened the closing ductus of new-born rats, rabbits, and lambs. These observations led to the investigation of alprostadil in infants who had congenital defects which restricted the pulmonary or systemic blood flow and who depended on a patent ductus arteriosus for adequate blood oxygenation and lower body perfusion.

In infants with restricted pulmonary blood flow, about 50% responded to alprostadil infusion with at least a 10 torr increase in blood pO2 (mean increase about 14 torr and mean increase in oxygen saturation about 23%). In general, patients who responded best had low pretreatment blood pO2 and were 4 days old or less.

In infants with restricted systemic blood flow, alprostadil often increased pH in those having acidosis, increased systemic blood pressure, and decreased the ratio of pulmonary artery pressure to aortic pressure.

Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by β- and ω- oxidation. The metabolites are excreted primarily by the kidney, and excretion is essentially complete within 24 hours after administration. No unchanged alprostadil has been found in the urine, and there is no evidence of tissue retention of alprostadil or its metabolites.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects.

In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO2 values; that is, patients with low pO2 values respond best, and patients with pO2 values of 40 torr or more usually have little response.

PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

None.

WARNINGS

WARNINGS SECTION

See WARNING box.

NOTE: PROSTIN VR PEDIATRIC Sterile Solution must be diluted before it is administered. See dilution instructions in DOSAGE AND ADMINISTRATION section.

The administration of PROSTIN VR PEDIATRIC to neonates may result in gastric outlet obstruction secondary to antral hyperplasia. This effect appears to be related to duration of therapy and cumulative dose of the drug. Neonates receiving PROSTIN VR PEDIATRIC at recommended doses for more than 120 hours should be closely monitored for evidence of antral hyperplasia and gastric outlet obstruction.

PROSTIN VR PEDIATRIC should be infused for the shortest time and at the lowest dose that will produce the desired effects. The risks of long-term infusion of PROSTIN VR PEDIATRIC should be weighed against the possible benefits that critically ill infants may derive from its administration.

PRECAUTIONS

PRECAUTIONS SECTION

General Precautions

GENERAL PRECAUTIONS SECTION

Cortical proliferation of the long bones, first observed in dogs, has also been observed in infants during long-term infusions of alprostadil. The cortical proliferation in infants regressed after withdrawal of the drug.

In infants treated with PROSTIN VR PEDIATRIC at the usual doses for 10 hours to 12 days and who died of causes unrelated to ductus structural weakness, tissue sections of the ductus and pulmonary arteries have shown intimal lacerations, a decrease in medial muscularity and disruption of the medial and internal elastic lamina. Localized and aneurysmal dilatations and vessel wall edema also were seen compared to a series of pathological specimens from infants not treated with PROSTIN VR PEDIATRIC. The incidence of such structural alterations has not been defined.

Because alprostadil inhibits platelet aggregation, use PROSTIN VR PEDIATRIC cautiously in neonates with bleeding tendencies.

PROSTIN VR PEDIATRIC should not be used in neonates with respiratory distress syndrome. A differential diagnosis should be made between respiratory distress syndrome (hyaline membrane disease) and cyanotic heart disease (restricted pulmonary blood flow). If full diagnostic facilities are not immediately available, cyanosis (pO2 less than 40 torr) and restricted pulmonary blood flow apparent on an X-ray are appropriate indicators of congenital heart defects.

Necessary Monitoring

SPL UNCLASSIFIED SECTION

In all neonates, arterial pressure should be monitored intermittently by umbilical artery catheter, auscultation, or with a Doppler transducer. Should arterial pressure fall significantly, decrease the rate of infusion immediately.

In infants with restricted pulmonary blood flow, measure efficacy of PROSTIN VR PEDIATRIC by monitoring improvement in blood oxygenation. In infants with restricted systemic blood flow, measure efficacy by monitoring improvement of systemic blood pressure and blood pH.

PROSTIN VR PEDIATRIC contains ethanol (79% w/v). Ethanol may cause CNS depressant effects such as somnolence and may alter the effects of other medicines. Co‑administration with medicines containing e.g. propylene glycol or ethanol may lead to accumulation of ethanol and induce adverse effects, particularly in young children with low or immature metabolic capacity.

Drug Interactions

DRUG INTERACTIONS SECTION

No drug interactions have been reported between PROSTIN VR PEDIATRIC and the therapy standard in neonates with restricted pulmonary or systemic blood flow. Standard therapy includes antibiotics, such as penicillin and gentamicin; vasopressors, such as dopamine and isoproterenol; cardiac glycosides; and diuretics, such as furosemide.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term carcinogenicity studies and fertility studies have not been done. The Ames and Alkaline Elution assays reveal no potential for mutagenesis.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Central Nervous System

SPL UNCLASSIFIED SECTION

Apnea has been reported in about 12% of the neonates treated. (See WARNING box.) Other common adverse reactions reported have been fever in about 14% of the patients treated and seizures in about 4%. The following reactions have been reported in less than 1% of the patients: cerebral bleeding, hyperextension of the neck, hyperirritability, hypothermia, jitteriness, lethargy, and stiffness.

Cardiovascular System

SPL UNCLASSIFIED SECTION

The most common adverse reactions reported have been flushing in about 10% of patients (more common after intraarterial dosing), bradycardia in about 7%, hypotension in about 4%, tachycardia in about 3%, cardiac arrest in about 1%, and edema in about 1%. The following reactions have been reported in less than 1% of the patients: congestive heart failure, hyperemia, second degree heart block, shock, spasm of the right ventricle infundibulum, supraventricular tachycardia, and ventricular fibrillation.

Respiratory System

SPL UNCLASSIFIED SECTION

The following reactions have been reported in less than 1% of the patients: bradypnea, bronchial wheezing, hypercapnia, respiratory depression, respiratory distress, and tachypnea.

Gastrointestinal System

SPL UNCLASSIFIED SECTION

See WARNINGS

The most common adverse reaction reported has been diarrhea in about 2% of the patients. The following reactions have been reported in less than 1% of the patients: gastric regurgitation, and hyperbilirubinemia.

Hematologic System

SPL UNCLASSIFIED SECTION

The most common hematologic event reported has been disseminated intravascular coagulation in about 1% of the patients. The following events have been reported in less than 1% of the patients: anemia, bleeding, and thrombocytopenia.

Excretory System

SPL UNCLASSIFIED SECTION

Anuria and hematuria have been reported in less than 1% of the patients.

Skeletal System

SPL UNCLASSIFIED SECTION

Cortical proliferation of the long bones has been reported. See PRECAUTIONS.

Miscellaneous

SPL UNCLASSIFIED SECTION

Sepsis has been reported in about 2% of the patients. Peritonitis has been reported in less than 1% of the patients. Hypokalemia has been reported in about 1%, and hypoglycemia and hyperkalemia have been reported in less than 1% of the patients.

OVERDOSAGE

OVERDOSAGE SECTION

Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage. If apnea or bradycardia occurs, discontinue the infusion, and provide appropriate medical treatment. Caution should be used in restarting the infusion. If pyrexia or hypotension occurs, reduce the infusion rate until these symptoms subside. Flushing is usually a result of incorrect intraarterial catheter placement, and the catheter should be repositioned.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The preferred route of administration for PROSTIN VR PEDIATRIC Sterile Solution is continuous intravenous infusion into a large vein. Alternatively, PROSTIN VR PEDIATRIC may be administered through an umbilical artery catheter placed at the ductal opening. Increases in blood pO2 (torr) have been the same in neonates who received the drug by either route of administration.

Begin infusion with 0.05 to 0.1 micrograms alprostadil per kilogram of body weight per minute. A starting dose of 0.1 micrograms per kilogram of body weight per minute is the recommended starting dose based on clinical studies; however, adequate clinical response has been reported using a starting dose of 0.05 micrograms per kilogram of body weight per minute. After a therapeutic response is achieved (increased pO2 in infants with restricted pulmonary blood flow or increased systemic blood pressure and blood pH in infants with restricted systemic blood flow), reduce the infusion rate to provide the lowest possible dosage that maintains the response. This may be accomplished by reducing the dosage from 0.1 to 0.05 to 0.025 to 0.01 micrograms per kilogram of body weight per minute. If response to 0.05 micrograms per kilogram of body weight per minute is inadequate, dosage can be increased up to 0.4 micrograms per kilogram of body weight per minute although, in general, higher infusion rates do not produce greater effects.

Dilution Instructions

SPL UNCLASSIFIED SECTION

To prepare infusion solutions, dilute 1 mL of PROSTIN VR PEDIATRIC Sterile Solution with Sodium Chloride Injection USP or Dextrose Injection USP. Undiluted PROSTIN VR PEDIATRIC Sterile Solution may interact with the plastic sidewalls of volumetric infusion chambers causing a change in the appearance of the chamber and creating a hazy solution. Should this occur, the solution and the volumetric infusion chamber should be replaced.

When using a volumetric infusion chamber, the appropriate amount of intravenous infusion solution should be added to the chamber first. The undiluted PROSTIN VR PEDIATRIC Sterile Solution should then be added to the intravenous infusion solution, avoiding direct contact of the undiluted solution with the walls of the volumetric infusion chamber.

Dilute to volumes appropriate for the pump delivery system available. Prepare fresh infusion solutions every 24 hours. Discard any solution more than 24 hours old.

Sample Dilutions and Infusion Rates to Provide a Dosage of 0.1 Micrograms per Kilogram of Body Weight per Minute
Add 1 ampoule
(500 micrograms)
alprostadil to:
Approximate Concentration of resulting solution
(micrograms/mL)
Infusion rate
(mL/min per kg of body weight)
Example: To provide 0.1 micrograms/kilogram of body weight per minute to an infant weighing 2.8 kilograms using a solution of 1 ampoule PROSTIN VR PEDIATRIC in 100 mL of saline or dextrose: INFUSION RATE = 0.02 mL/min per kg × 2.8 kg = 0.056 mL/min or 3.36 mL/hr.

250 mL

2

0.05

100 mL

5

0.02

50 mL

10

0.01

25 mL

20

0.005

HOW SUPPLIED

HOW SUPPLIED SECTION

PROSTIN VR PEDIATRIC Sterile Solution is available in a package of 5 ×1 mL ampoules (NDC 0009-0215-05). Each mL contains 500 micrograms alprostadil in dehydrated alcohol.

STORAGE AND HANDLING SECTION

Store PROSTIN VR PEDIATRIC Sterile Solution in a refrigerator at 2° to 8°C (36° to 46°F).

SPL UNCLASSIFIED SECTION

Rx only

Distributed by
Pharmacia & Upjohn Company LLC
A subsidiary of Pfizer Inc.
New York, NY 10001

Logo
Logo

Novaplus is a registered trademark of Vizient, Inc.

LAB-1522-3.0
Revised April 2026

PRINCIPAL DISPLAY PANEL - 1 mL Ampoule Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0009-0215-01
Rx ONLY

Prostin VR Pediatric®
(alprostadil) injection, USP

For Intravenous Use Only.
Dilute Before Use.

1 mL

500 mcg/mL

Refrigerate at 2° to 8°C (36° to 46°F).

Dist. by Pharmacia & Upjohn Co. LLC
A sub. of Pfizer Inc.
NY, NY 10001

novaplus™

PAA250300

LOT

EXP

PRINCIPAL DISPLAY PANEL - 1 mL Ampoule Label
PRINCIPAL DISPLAY PANEL - 1 mL Ampoule Label

PRINCIPAL DISPLAY PANEL - 1 mL Ampoule Package

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0009-0215-05

Prostin VR Pediatric®
(alprostadil) injection, USP

500 mcg/mL

5—1 mL Ampoules

For Intravenous Use Only.
Dilute Before Use.

Rx ONLY

novaplus™

PRINCIPAL DISPLAY PANEL - 1 mL Ampoule Package
PRINCIPAL DISPLAY PANEL - 1 mL Ampoule Package

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeDataBar Limited(01)10300090215016GTIN-14: 10300090215016
GTIN storage (14 digits): 10300090215016
prostin-03.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
4a3c3468-d7dd-dbc7-68a7-e177b6ff0c9cProduct name120140508
9a159c5b-579d-e616-cae2-48cf73594159Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0009-0215-01ML - Milliliter0009-0215e8e9ad16-13d6-4c4b-ad99-fbc4ffabe4cc12022-11-07
0009-0215-05ML - Milliliter0009-02152cd165fa-8dfb-4f8e-9985-659ee09e27f212022-11-07

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0009-02150009-0215-01, 0009-0215-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Name, UNII, Kind table
NameUNIIKind
ALPROSTADILF5TD010360ACTIB
ALCOHOL3K9958V90MIACT

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
32026-05-19full-release2026-05-31 22:20:25
22026-02-19monthly-update2026-06-03 17:57:47

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N018484-001PROSTIN VR PEDIATRICALPROSTADIL0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N018484-001AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982d4dbc9d85df4…
2026-10-15 13:18:302026-09N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982c2088c7a36db…
2026-09-14 22:38:342026-08N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N018484-001PROSTIN VR PEDIATRIC0.5MG/MLINJECTABLE / INJECTIONAPRLD, RS, Approved before 19823bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10N018484-001AP1d4dbc9d85df4…
2026-10-15 13:18:302026-09N018484-001AP1c2088c7a36db…
2026-09-14 22:38:342026-08N018484-001AP184e616aacf4f…
2026-08-18 06:07:402026-07N018484-001AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018484-001AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018484-001AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08N018484-001AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018484-001AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018484-001AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018484-001AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018484-001AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018484-001AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018484-001AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018484-001AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018484-001AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018484-001AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018484-001AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N018484-001AP18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018484-001AP15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N018484-001AP15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N018484-001AP14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N018484-001AP174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N018484-001AP1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N018484-001AP1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N018484-001AP187673890dc5c…
2021-03-12 10:30 UTC2021-03N018484-001AP15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N018484-001AP18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N018484-001AP1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N018484-001AP13f01610625f2…
2019-09-15 20:21 UTC2019-09N018484-001AP1b00525d2431f…
2019-07-19 19:46 UTC2019-07N018484-001AP1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N018484-001AP16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N018484-001AP11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N018484-001AP1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N018484-001AP1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N018484-001AP19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N018484-001AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N018484-001AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05N018484-001AP1053a50430f4f…
2023-01-26 05:58 UTC2023-01N018484-001AP13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
PROSTIN VR PEDIATRICALPROSTADILPharmacia & Upjohn Company LLC930f8c02-46a8-4cff-a484-660468ab23c32026-08-17Boxed warning, Warnings, Adverse reactionsExact identifier
ndc (package): 0009-0215-05
ndc (package): 0009-0215-01
ndc (product): 0009-0215
ndc11 (package): 00009021501
ndc11 (package): 00009021505
spl id: 77f50b86-f209-4f15-9dde-1e348635598e
spl set id: 930f8c02-46a8-4cff-a484-660468ab23c3

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.